- Home
- IVCA vs APLT Comparison
IVCA vs APLT Comparison
Compare IVCA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVCA
- APLT
- Stock Information
- Founded
- IVCA 2021
- APLT 2016
- Country
- IVCA Cayman Islands
- APLT United States
- Employees
- IVCA N/A
- APLT N/A
- Industry
- IVCA Blank Checks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- IVCA Finance
- APLT Health Care
- Exchange
- IVCA Nasdaq
- APLT Nasdaq
- Market Cap
- IVCA 93.8M
- APLT 80.3M
- IPO Year
- IVCA 2022
- APLT 2019
- Fundamental
- Price
- IVCA $11.82
- APLT $0.53
- Analyst Decision
- IVCA
- APLT Buy
- Analyst Count
- IVCA 0
- APLT 7
- Target Price
- IVCA N/A
- APLT $6.10
- AVG Volume (30 Days)
- IVCA 301.0
- APLT 3.0M
- Earning Date
- IVCA 01-01-0001
- APLT 03-05-2025
- Dividend Yield
- IVCA N/A
- APLT N/A
- EPS Growth
- IVCA N/A
- APLT N/A
- EPS
- IVCA 0.26
- APLT N/A
- Revenue
- IVCA N/A
- APLT N/A
- Revenue This Year
- IVCA N/A
- APLT N/A
- Revenue Next Year
- IVCA N/A
- APLT $2,622.90
- P/E Ratio
- IVCA $45.87
- APLT N/A
- Revenue Growth
- IVCA N/A
- APLT N/A
- 52 Week Low
- IVCA $11.10
- APLT $0.53
- 52 Week High
- IVCA $12.37
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- IVCA 41.74
- APLT 29.75
- Support Level
- IVCA $11.81
- APLT $0.54
- Resistance Level
- IVCA $12.03
- APLT $0.70
- Average True Range (ATR)
- IVCA 0.02
- APLT 0.06
- MACD
- IVCA -0.01
- APLT 0.06
- Stochastic Oscillator
- IVCA 5.26
- APLT 0.00
About IVCA Investcorp India Acquisition Corp.
Investcorp AI Acquisition Corp is a blank check company.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.